GoodRx Holdings, Inc. GDRX Pharma Direct revenue — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by GoodRx Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: GoodRx Holdings, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about GoodRx Holdings, Inc.'s pharma direct revenue — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is GoodRx Holdings, Inc.'s pharma direct revenue — revenue?
- GoodRx Holdings, Inc. (GDRX) reported pharma direct revenue — revenue of $52.23M in Q1 2026.
- How has GoodRx Holdings, Inc.'s pharma direct revenue — revenue changed year-over-year?
- GoodRx Holdings, Inc.'s pharma direct revenue — revenue increased by 82.3% year-over-year, from $28.65M to $52.23M.
- What is the long-term trend for GoodRx Holdings, Inc.'s pharma direct revenue — revenue?
- Over 3 years (2021 to 2024), GoodRx Holdings, Inc.'s pharma direct revenue — revenue has grown at a 13.5% compound annual growth rate (CAGR), from $73.35M to $107.24M.
- What does pharma direct revenue — revenue mean?
- This metric represents revenue generated from pharmaceutical manufacturers through direct marketing and promotional solutions on the platform. It reflects the company's ability to monetize its user base by connecting drug makers with consumers and healthcare providers for brand awareness and patient access programs. This revenue stream is a key indicator of the platform's utility as a digital advertising and engagement channel for the life sciences industry.